XGN EXAGEN INC. Insider Trading

10% owner NMSIC Co-Investment Fund sold 350,000 shares of XGN at $3.30 (-22% discount to current $4.24); stock unprofitable, -29.3% from 52-week high.

NMSIC Co-Investment Fund, a 10% owner of EXAGEN INC., sold 350,000 shares (16.6% reduction in holdings) at $3.30 per share on 2025-03-25, collecting $1,155,000.00. The transaction occurred at a 22% discount to the current price of $4.24, and notably preceded a recent 30-day rally of +22.9%. The company remains unprofitable with net income of $-5,028,000.00 in the latest quarter despite modest 5.9% annual revenue growth, suggesting the sale by a major shareholder occurred during a period of negative earnings and equity market conditions. The stock's 52-week trading range ($1.36–$6.00) and current position 29.3% below its high indicates persistent volatility and earlier market weakness at the time of sale.

CFO Jeffrey G. Black bought 22,298 shares of XGN at $2.98; stock near 52-week high of $3.53 as unprofitable biotech seeks growth.

On 2024-11-15, Black Jeffrey G., Chief Financial Officer, purchased 22,298 shares at $2.98, increasing his holdings by 8.8% to 274,492 shares. The transaction occurs near the stock's 52-week high of $3.53 and follows a 22.6% 30-day price rise. Despite revenue growth of 15.3% year-over-year, EXAGEN remains unprofitable, with a net loss of $5,028,000.00 in the latest full fiscal year and a quarterly net loss of $5,028,000.00 against $12,507,000.00 in revenue. The combination of an insider buy from the CFO during a strong price run-up—while the company remains structurally unprofitable—merits careful attention to whether this reflects conviction in a turnaround path or a timed response to recent momentum.

CEO Aballi buys 24,305 shares of XGN at $2.81, raising stake to 689.8K shares as company pursues growth amid profitability challenges.

President and CEO John Aballi purchased 24,305 shares at $2.81 on 2024-11-14, increasing his holdings from 665.5K to 689.8K shares (+3.7%). The transaction occurred at a price 6.3% below the current $3.00 level and well below the 52-week high of $3.42. Aballi's prior purchase at this same ticker on 2024-05-16 delivered 90-day returns of +49.0%, establishing a demonstrated pattern of well-timed entry timing. The company is growing revenues at +15.3% annually but remains unprofitable, with latest quarterly net income of $-5.0M against $12.5M in revenue, creating a mixed signal: management's share accumulation suggests confidence in turnaround prospects, yet the company's current cash burn and market cap of $52.9M warrant investor scrutiny of whether execution can bridge to profitability.